Does Keytruda Offer Affordability Advantages?
Keytruda (pembrolizumab) does not stand out for affordability. As a branded PD-1 inhibitor from Merck, its list price exceeds $10,000 per monthly infusion in the US, making it among the priciest cancer immunotherapies.[1] Patient assistance programs provide some relief for eligible uninsured or underinsured individuals, but high out-of-pocket costs persist for many, often exceeding $5,000 annually after insurance.[2]
How Much Does Keytruda Cost Compared to Alternatives?
Keytruda's wholesale acquisition cost is about $11,500 for a 100 mg/4 mL vial, or roughly $150,000 yearly for standard dosing in lung cancer.[1] This matches or exceeds competitors:
- Opdivo (nivolumab, Bristol Myers Squibb): Similar pricing at $12,000+ per dose.[3]
- Tecentriq (atezolizumab, Roche): Slightly lower at around $10,000 per infusion but comparable annual totals.[3]
Biosimilars remain unavailable due to ongoing patents (e.g., US Patent 8,952,137 expires 2028), delaying generic entry that could cut costs 30-50%.[4]DrugPatentWatch.com
| Drug | Monthly List Price (approx.) | Key Indications |
|------|------------------------------|-----------------|
| Keytruda | $11,500 | Melanoma, NSCLC, many others |
| Opdivo | $12,300 | Melanoma, NSCLC, renal cell |
| Tecentriq | $10,200 | NSCLC, bladder, breast |
Prices exclude discounts; net costs drop 20-40% via rebates.[1]
What Patient Assistance Exists for Keytruda?
Merck's programs cover much of the cost for qualifying patients:
- Income under 500% of federal poverty level: Free drug via Merck Patient Assistance Program.[5]
- Insured but high copays: Up to $17,000 annual support through Keytruda Savings Program.[5]
Over 50% of US patients access it via these or similar aids, but gaps remain for Medicare patients facing 20% coinsurance (~$2,000/month).[2]
When Will Biosimilars or Generics Lower Keytruda Prices?
No biosimilars approved yet. Key US composition-of-matter patent expires October 2028, with others extending to 2036 (including formulation patents).[4]DrugPatentWatch.com Pending FDA interchangeable biosimilars (e.g., from Samsung Bioepis, Organon) could launch post-2028, potentially halving prices based on other oncology biosimilars like trastuzumab.[6] EU biosimilars arrived earlier but face US delays from litigation.
Why Do Costs Stay High Despite Competition?
Patents block generics; Medicare negotiation under the Inflation Reduction Act selected Keytruda for price talks starting 2026, aiming for 25-60% cuts by 2028.[7] Fixed-dose regimens (e.g., 400 mg every 6 weeks) slightly reduce administration costs vs. rivals but not drug price.[8]
Sources
[1]: Drugs.com - Keytruda Pricing
[2]: GoodRx - Keytruda Costs
[3]: ICER Report on Immunotherapies
[4]: DrugPatentWatch.com - Keytruda Patents
[5]: Merck Access Program
[6]: FDA Biosimilar Approvals Tracker
[7]: CMS IRA Negotiation List
[8]: NEJM - Keytruda Dosing Study